To celebrate the luncheon's 10th year, the National Multiple Sclerosis Society, a nonprofit with an office in Hauppauge, wanted to do something different, so she suggested a fashion show.

Company News Published 06/03/2025, 10:53 AM 0 CARVYKTI shows lasting impact in multiple myeloma treatment LEGN 2.25% ...

Company News Published 05/23/2025, 07:18 AM 0 CHMP endorses Blenrep for multiple myeloma treatment GSK -0.13% ...

CellCentric’s $120 million Series C funding supports late-stage development of inobrodib, a novel oral p300/CBP inhibitor for multiple myeloma. Inobrodib’s mechanism targets MYC and IRF4 expression, ...

This new treatment represents a significant advancement for patients suffering from multiple myeloma one of the most challenging and life-threatening types of blood cancer, accounting for 15% of all ...

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) Q1 2025 Results Conference Call May 7, 2025 4:30 PM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, Chairman and CEO Tim ...

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. Learn more on IBRX stock here.

The increase in high-efficacy treatment use -- primarily rituximab -- was 89% among Hispanic MS patients, 87% among Black patients, and 83% among White patients after the program was implemented.

Ocugen, Inc. will present on its modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt ...

Minimal residual disease (MRD) is a key focus in multiple myeloma treatment decision-making, offering prognostic insights and potential treatment guidance. Clinicians use MRD variably, with some ...

HOUSTON – Multiple sclerosis, or MS, affects a million Americans a year. It can lead to a range of symptoms, from fatigue and numbness to more severe issues like mobility problems and vision loss.

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022.